RA Capital

JOHN AVERILL

Associate

John is an Associate with the TechAtlas division of RA Capital. John's primary responsibilities at RA are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context and to advise RA's portfolio companies on many aspects of program and pipeline strategy. John has his MBA from MIT Sloan School of Management. Prior to his time at Sloan, he worked at Intellia as an Associate Scientist. John holds a Bachelor's Degree in Cell/Cellular and Molecular Biology from the University of Connecticut.

DANIEL MACAYA, PhD

Senior Director of Corporate Development

Daniel Macaya is Senior Director of Corporate Development at RA Ventures (RAVen), focusing on new company creation. Prior to RAVen, Daniel co-founded and led strategy and operations for Seeker Biologics, Series A funded multi-specific biologics platform company aimed at discovering precision medicines for inflammatory disease. Prior to this, Daniel was an Associate Director within the TechAtlas division of RA Capital Management where he drove internal and external strategic and diligence initiatives and oversaw the workflow and professional development of TechAtlas Associates. Prior to this role, as an Associate at RA Capital, Daniel mapped a diverse range of competitive landscapes, spanning autoimmune, oncology, neurologic, and metabolic diseases, as well as the pipelines of several large pharma. Daniel holds a PhD in Medical Engineering from the Harvard-MIT division of Health Sciences and Technology, where his research focused on the development of tissue engineered grafts capable of restoring function after spinal cord injury, and a BS in Materials Science from Cornell University.

PHI THACH

Executive Assistant

Phi Thach is an Executive Assistant at RA Capital Management. Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. Phi previously worked as an Executive Assistant at Relay Therapeutics. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College.

J. MICHAEL RYAN, MD

Michael Ryan was an EIR at RA Capital. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004.

LAURA STOPPEL, PhD

Principal

Laura Stoppel is a Principal on the Investment Team at RA Capital Management. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.

PEYMAN HOSSEINCHI, PhD

RA Ventures Associate

Peyman Hosseinchi is an Associate at RA Ventures. Peyman's primary responsibility is NewCo creation in collaboration with Ventures Partners and EIRs at RA Ventures. Prior to joining RAVen, Peyman was an Associate within the TechAtlas division of RA Capital, focusing on identifying emerging therapeutics and advising RA Capital's portfolio companies on their pipeline. Peyman holds a dual B.S. in Mechanical & Aerospace Engineering from Sharif University of Technology, Tehran, Iran and a PhD in Molecular Engineering from Pritzker School of Molecular Engineering, University of Chicago.